EVENTS | VIEW CALENDAR
Mount Sinai School of Medicine gets first Trilogy Instrument from U.S. Genomics
WOBURN, Mass.—U.S. Genomics announced late last year placement of its first Trilogy Single Molecule Analyzer, with the Life Sciences Technology Laboratory at New York's Mount Sinai School of Medicine.
"Mount Sinai is an international leader for cutting-edge life science and biomedical research," said Stephen P. DeFalco, chairman and chief exective officer of U.S. Genomics. "We are delighted to work with the prominent researchers of Mount Sinai and look forward to advancing scientific discovery through the use of single molecule biology on the Trilogy platform."
The first Trilogy platform installation includes an instrument and associated reagents to support a variety of direct, single molecule assays in a 96-well format.